Accelerator Network

Renovion Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of Non-CF Bronchiectasis

Retrieved on: 
Wednesday, November 2, 2022
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Accelerator Network, Awareness, Inflammation, Chronic cough, Pulmonology, Respiratory disease, Disease, Bronchiectasis, Degenerative disease, Cough, Safety, COPD, Adoption, Education, Foundation, Therapy, FDA, NTM, Patient, Mucus, Death, Drug development, Quality of life, Infection, Pharmaceutical industry

Renovion and COPD Foundation Joint Release Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFBE) ( NCT05495243 ).

Key Points: 
  • Renovion and COPD Foundation Joint Release Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFBE) ( NCT05495243 ).
  • The Phase 2 study is a multicenter, randomized, double-blind, placebo-controlled clinical trial.
  • As a partner with Renovion through our therapeutics and digital health accelerator 360Net, were pleased to see that the ARINA-1 Phase 2 clinical study has its first patient enrolled.
  • Renovion is a clinical stage pharmaceutical company focused on developing ARINA-1, novel nebulized therapy delivered to the lungs to treat pulmonary diseases.

Class Intercom Set to Host Third Annual Digital Content Creation Workshop for Students & Educators

Retrieved on: 
Friday, October 14, 2022
Accelerator Network, Education, Global, Professional learning community, PLC, Technology, Student, Software, CEO, Social media, School, Tutoring

LINCOLN, Neb., Oct. 14, 2022 /PRNewswire/ -- Class Intercom , the leading provider of social media management software for schools and school districts, will host its annual Content Generation Workshop on November 1, 2022.

Key Points: 
  • LINCOLN, Neb., Oct. 14, 2022 /PRNewswire/ -- Class Intercom , the leading provider of social media management software for schools and school districts, will host its annual Content Generation Workshop on November 1, 2022.
  • "The Content Generation Workshop provides these exact opportunities while coaching students and teachers as they learn and grow as creators.
  • "Exposure to professional content creators helps students and educators hone and sharpen their skills as digital content creators," explains Class Intercom President Dr. Jill Johnson, herself a former teacher and administrator with 30 years of experience in education.
  • "The Content Generation Workshop is a unique opportunity for hands-on, experiential learning and we're thrilled to host another cohort of students and educators."

ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray

Retrieved on: 
Wednesday, February 23, 2022
Accelerator Network, Risk, Conditional sentence, CDC, Virus, Chronic obstructive pulmonary disease, Education, Awareness, ENA, COVID-19, Severe acute respiratory syndrome coronavirus 2, Chronic cough, NTM, Incidence, Infection, Therapy, Rhinovirus, Partnership, Human, AECOPD, Post-exposure prophylaxis, Interview, Fever, Disease, Mark (given name), Adoption, Epithelium, CEO, Degenerative disease, Respiratory tract, Twitter, Efficiency, Mucus, Fatigue, LinkedIn, Hospital, Patient, Digital health, Bronchiectasis, GLOBE, Mid-Tertiary ignimbrite flare-up, Death, Asthma, Respiratory disease, RSV, Foundation, Chronic lung disease, Nasal mucosa, Vaccine, Pharmaceutical industry, H1N1, COPD

SYDNEY, Australia and MIAMI, Feb. 23, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19 in populations at-risk of complications, and the COPD Foundation, a not-for-profit organization focused on improving the lives of those affected by COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease, announced a partnership to develop INNA-051 in people with chronic lung diseases.

Key Points: 
  • Respiratory virus infections, especially rhinovirus (the common cold), respiratory syncytial virus (RSV), and influenza, are related to worsening of chronic lung conditions, including chronic obstructive pulmonary disease (COPD) and asthma.
  • We are excited to partner with ENA Respiratory to advance the development of INNA-051, said Ruth Tal-Singer, Ph.D., COPD Foundation President & Chief Scientific Officer.
  • The expertise of the COPD Foundation and the shared commitment of the Foundation and ENA Respiratory to patient-centred drug development will allow the INNA-051 clinical program to progress with maximum efficiency.
  • We are thrilled to partner with the COPD Foundation to support the clinical development of INNA-051 in chronic lung diseases.

Renovion and the COPD Foundation Launch COPD and Bronchiectasis Development Partnership to Address Unmet Patient Need

Retrieved on: 
Tuesday, September 21, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Accelerator Network, Degenerative disease, Adoption, Partnership, Digital health, Efficiency, Mucus, NTM, Bronchiectasis, Chronic obstructive pulmonary disease, Inflammation, Therapy, Chronic lung disease, University of North Carolina at Chapel Hill, Patient, Respiratory disease, CEO, Death, Communication, Awareness, Research, Drug development, COPD, UNC, Safety, Foundation, Doctor of Philosophy, Education, Pharmaceutical industry, Renovion, The COPD Foundation and COPD360Net, RENOVION, THE COPD FOUNDATION AND COPD360NET

Together, Renovion and the COPD Foundation are leveraging the foundational research in bronchiectasis registries and COPD studies, such as those utilizing the SPIROMICS and COPDGene groups that demonstrate a need for therapies that target airway mucus plugging.

Key Points: 
  • Together, Renovion and the COPD Foundation are leveraging the foundational research in bronchiectasis registries and COPD studies, such as those utilizing the SPIROMICS and COPDGene groups that demonstrate a need for therapies that target airway mucus plugging.
  • The unique collaborative approach of the COPD Foundations global partnerships and COPD360Net allows for patient-centered drug development to accelerate clinical programs.
  • Finding the right patient target for clinical trials is a primary challenge of drug development today and this is especially true in the COPD and bronchiectasis patient populations.
  • It aims to accelerate the development of a therapeutic COPD360Net pipeline asset that may benefit individuals with COPD and / or bronchiectasis.